Market Reactions

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

The failed LEVEL study weakens the case for a first drug for PH‑HFpEF and pushes the company to pursue narrow regulatory options based on exploratory signals.